A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2023.2171994
Abstract: ABSTRACT Background In the ZUMA-5 trial (Clinical trials identification: NCT03105336), axicabtagene ciloleucel (axi-cel; a chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory (r/r) follicular lymphoma (FL) patients and clear superiority… read more here.
Keywords: zuma; axi cel; analysis; relapsed refractory ... See more keywords
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021014375
Abstract: As yet, there are no randomized studies of chimeric antigen receptor (CAR) T-cell therapy versus standard therapy in patients with multiple relapsed follicular lymphoma. To provide early insight into comparative efficacy, Ghione et al used… read more here.
Keywords: axi; follicular lymphoma; axi cel; zuma ... See more keywords